GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viking Therapeutics Inc (NAS:VKTX) » Definitions » Institutional Ownership

VKTX (Viking Therapeutics) Institutional Ownership : 79.46% (As of Dec. 11, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Viking Therapeutics Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Viking Therapeutics's institutional ownership is 79.46%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Viking Therapeutics's Insider Ownership is 3.86%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Viking Therapeutics's Float Percentage Of Total Shares Outstanding is 74.45%.


Viking Therapeutics Institutional Ownership Historical Data

The historical data trend for Viking Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viking Therapeutics Institutional Ownership Chart

Viking Therapeutics Historical Data

The historical data trend for Viking Therapeutics can be seen below:

2024-02-29 2024-03-31 2024-04-30 2024-05-31 2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30
Institutional Ownership 57.67 55.08 54.70 55.26 56.99 56.78 56.93 55.94 55.54 55.48

Viking Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Viking Therapeutics Business Description

Traded in Other Exchanges
Address
9920 Pacific Heights Boulevard, Suite 350, San Diego, CA, USA, 92121
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Executives
Lawson Macartney director C/O AMBRX, INC., 10975 N. TORREY PINES RD., LA JOLLA CA 92037
Greg Zante officer: Chief Financial Officer C/O SANGAMO BIOSCIENCES, INC STE-A-100, POINT RICHMOND TECH, 501 CANAL BLVD,, RICHMOND CA 94804
Sarah Kathryn Rouan director 4995 BRADENTON AVENUE, SUITE 240, DUBLIN OH 43017
J Matthew Singleton director 286 STANWICH ROAD, GREENWICH CT 06830
Brian Lian director, officer: President & CEO C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Marianna Mancini officer: Chief Operating Officer C/O VIKING THERAPEUTICS, INC., 12340 EL CAMINO REAL, STE 250, SAN DIEGO CA 92130
Rowland Charles A Jr director 3338 LANCASHIRE RD, FURLONG PA 18925
Matthew W Foehr director 11119 NORTH TORREY PINES RD #200, LA JOLLA CA 92037
Ligand Pharmaceuticals Inc 10 percent owner 3911 SORRENTO VALLEY BLVD, SUITE 110, SAN DIEGO CA 92121
Hiroko Masamune officer: Chief Development Officer C/O VIKING THERAPEUTICS, INC., 12340 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130
Michael Morneau officer: Chief Financial Officer C/O TRIUS THERAPEUTICS, INC., 6410 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Stephen W Webster director C/O OPTIMER PHARMACEUTICALS, INC, 101 HUDSON STREET, SAN DIEGO CA 07302
Rochelle Hanley officer: Chief Medical Officer C/O VIKING THERAPEUTICS, INC., 11119 NORTH TORREY PINES ROAD, SUITE 50, SAN DIEGO CA 92037
Michael Dinerman officer: Chief Operating Officer C/O VIKING THERAPEUTICS, INC., 11119 NORTH TORREY PINES ROAD, SUITE 50, SAN DIEGO CA 92037